What is liver disease? What is pancreatic cancer? Contact Us

How do I get treatment?

For further information and appointments please contact us:

Call us

Follow up of head and neck cancer treatment London

Following completion of the head and neck cancer treatment in London, be it surgery or radiotherapy or both, all patients will be followed up for a minimum of five years. For the first post treatment year patients are followed up monthly, bi monthy for the second year, quartely for the third year and with an extra months interval for each additional year.

Normally follow up of head and neck cancer treatment in London will consist of clinical examination only but for inaccessible tumours this will include examination with a flexible nasendoscope (used to examine the nose and upper airways). MRI and CT scans are not used for routine follow up, rather only to clarify if there is a recurrence. Positron Emmision Tomography (PET Scanning) can also be used three months after treatment for the confirmation of recurrence.
It is best utilised with other modes of investigation such as MRI and CT.

Of those tumours that reccur 67 percent do so in the first year after treatment and 85 percent within two years. Thereafter recurrence is hence far less common and probably the result of a new tumour rather than recurrence.

If a recurrence is detected and confirmed the patient will have to be fully investigated and treatment determined by the multidisciplinary team.

Treatment is likely to be surgery if the recurrence is deemed “resectable”, almost certainly with additional radiotherapy, if the area has not been previously irradiated.

If the recurrence is not treatable, as much as possible will be done to palliate the patients condition, making them feel as comfortable and as pain free as possible. This is usually with analgesia though this may even involve radiotherapy, chemotherapy or surgery and photodynamic therapy may also be useful here.

Members of the team at the centre have published five year survival rates of as much as 87 percent for early disease on presentation, 43 percent of those with advanced disease surviving to five years.

Please note, all outcomes are audited.